Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460830 | 0.88 | PTGS1 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7797212 | 0.81 | ALOX5 (0.43) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4779257 | 0.78 | ALOX5 (0.51) | PSEN1ALOX5NR1I2 | |
| SCHEMBL2597432 | 0.78 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL11705987 | 0.78 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15150900 | 0.76 | PSEN1 (0.47) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL23961349 | 0.75 | PTGS1 (0.48) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL20822167 | 0.75 | PTPN1 (0.45) | PSEN1ALOX5NR1I2 | |
| SCHEMBL10445524 | 0.75 | PTGS1 (0.39) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL16282031 | 0.75 | ALOX5 (0.37) | CYP3A4TSHRALOX5NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | PTGS1 63/4885PTGS2 165/4885CYP1A2 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.